Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2454819 | 0.92 | HPGD (0.53) | ALDH1A1MEN1KMT2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL15330249 | 0.86 | ALDH1A1 (0.55) | ALDH1A1MAPK1MEN1KMT2ALMNA | |
| SCHEMBL1233804 | 0.84 | L3MBTL1 (0.65) | ALDH1A1MAPK1MEN1KMT2ALMNA | |
| SCHEMBL30222110 | 0.82 | PKM (0.61) | ALDH1A1PKMMAPK1MEN1KMT2A | |
| SCHEMBL15985305 | 0.82 | KMT2A (0.50) | ALDH1A1MEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL4661410 | 0.82 | PKM (0.61) | ALDH1A1PKMMAPK1MEN1KMT2A | |
| SCHEMBL5083356 | 0.82 | HPGD (0.51) | ALDH1A1MEN1KMT2ASMN1; SMN2MAP4K4 | |
| SCHEMBL398196 | 0.82 | ALDH1A1 (0.60) | ALDH1A1MAPK1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL955684 | 0.81 | HPGD (0.56) | ALDH1A1SMN1; SMN2TP53L3MBTL1 | |
| SCHEMBL177577 | 0.81 | SMN1; SMN2 (0.74) | ALDH1A1LMNASMN1; SMN2HTTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| US-20200181154-A1 | PYRAZOLE CARBOXAMIDE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2020-06-11 | — | — | US | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| US-20190194209-A1 | PYRAZOLE CARBOXAMIDE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2019-06-27 | — | — | US | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| US-20180057500-A1 | PYRAZOLE CARBOXAMIDE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2018-03-01 | — | — | US | disclosed |
| EP-3201186-A1 | PYRAZOLE CARBOXAMIDE COMPOUNDS FOR USE IN THE TREAMENT OF DISORDERS MEDIATED BY BRUTON'S TYROSINE KINASE (BTK) | F. Hoffmann-La Roche AG (CH) | 2017-08-09 | — | — | EP | disclosed |
| US-20160376286-A1 | Pyrimidin-4-one derivatives and their use in the tratement, amelioration or prevention of a viral disease | F. HOFFMAN-LA ROCHE LTD | 2016-12-29 | — | — | US | disclosed |
| US-20160297763-A1 | Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease | F. HOFFMANN-LA ROCHE LTD (CH) | 2016-10-13 | — | — | US | disclosed |
| WO-2010068292-A1 | AZAINDOLE DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | WO | disclosed |
| EP-2120579-A1 | INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | ABBOTT LABORATORIES (US) | 2009-11-25 | — | — | EP | disclosed |
| EP-2049539-A1 | PYRAZOLOPYRIMIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME. | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-04-22 | — | — | EP | disclosed |
| US-20080269234-A1 | Such as 7-((cyclohexyl)methyl) pyrido(2,3-d )pyridazine-4(5H)-one; anticancer agents; antiinflammatory agents;antiischemic agents; antidiabetic agents | ABBOTT LABORATORIES (US) | 2008-10-30 | — | — | US | disclosed |
| WO-2008083027-A1 | INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | ABBOTT LABORATORIES (US) | 2008-07-10 | — | — | WO | disclosed |
| US-20080161280-A1 | INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | ABBOTT LABORATORIES (US) | 2008-07-03 | — | — | US | disclosed |
| US-20080039455-A1 | PYRAZOLOPYRIMIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-02-14 | — | — | US | disclosed |
| EP-1873157-A1 | Pyrazolopyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-01-02 | — | — | EP | disclosed |
| WO-2007147647-A1 | PYRAZOLOPYRIMIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME. | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-12-27 | — | — | WO | disclosed |
| US-20070060573-A1 | Acyltryptophanols | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180057500-A1 | PYRAZOLE CARBOXAMIDE COMPOUNDS AND METHODS OF USE | BTK, IRAK3, IRAK1 | ALDH1A1 3327/4885PKM 422/4885MAPK1 287/4885 |
| US-20080269234-A1 | Such as 7-((cyclohexyl)methyl) pyrido(2,3-d )pyridazine-4(5H)-one; anticancer agents; antiinflammatory agents;antiischemic agents; antidiabetic agents | PARP1, DPYD, PARP2 | ALDH1A1 821/4885PKM 1248/4885MAPK1 2437/4885 |
| US-20080039455-A1 | PYRAZOLOPYRIMIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | DPYD, FLT1, PDXK | ALDH1A1 414/4885PKM 156/4885MAPK1 1247/4885 |
| US-20200181154-A1 | PYRAZOLE CARBOXAMIDE COMPOUNDS AND METHODS OF USE | BTK, IRAK3, IRAK1 | ALDH1A1 3327/4885PKM 422/4885MAPK1 287/4885 |
| US-20160376286-A1 | Pyrimidin-4-one derivatives and their use in the tratement, amelioration or prevention of a viral disease | TTR, TYMP, TPMT | ALDH1A1 464/4885PKM 1625/4885MAPK1 2142/4885 |
| US-20190194209-A1 | PYRAZOLE CARBOXAMIDE COMPOUNDS AND METHODS OF USE | BTK, IRAK3, IRAK1 | ALDH1A1 3327/4885PKM 422/4885MAPK1 287/4885 |
| US-20160297763-A1 | Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease | ALAD, CYP27A1, FAH | ALDH1A1 956/4885PKM 2736/4885MAPK1 2916/4885 |
| US-20070060573-A1 | Acyltryptophanols | FSHR, NPY1R, NPY2R | ALDH1A1 3830/4885PKM 3486/4885MAPK1 3998/4885 |
| US-20080161280-A1 | INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | PARP1, PARP2, PARP3 | ALDH1A1 1358/4885PKM 3750/4885MAPK1 4453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.